Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Angion Biomedica
company
About
Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease.
- 101 - 250
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $149.76K
- Industries
- Biopharma,Biotechnology,Medical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$149.76K
Angion Biomedica has raised a total of
$149.76K
in funding over 2 rounds. Their latest funding was raised on
Dec 11, 2013 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 11, 2013 | Grant | $149.76K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Angion Biomedica is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
